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 “It always seems impossible until it’s done” 
-Nelson Mandela- 
 
 
  
 
 
 

  
ABSTRACT  
Mammalian bHLH-Pas (basic HLH (helix-loop-helix)-PER-ARNT-SIM) proteins belong to 
the bHLH superfamily of transcription factors. Members of the family have a broad spectrum 
of functions that among others sense and regulate the cellular response to physiological 
signals such as low oxygen levels (hypoxia), or environmental signals such as toxins. The 
bHLH-Pas proteins consist of a signal-induced subunit, for example, aryl hydrocarbon 
receptor (AhR) or hypoxia inducible factor (HIF). To respond to environmental (AhR) or 
physiological (HIF) stimuli, the signal-induced subunits dimerize with their ubiquitously 
expressed, unregulated dimerization partner aryl hydrocarbon receptor nuclear translocator 
(ARNT), bind to DNA, and induce the activation of a cascade of target genes. At normal 
oxygen levels (normoxia), proline hydroxylases hydroxylate HIF, and the subsequent 
interaction of HIF with the von Hippel-Lindau tumor suppressor gene (pVHL) leads to 
ubiquitination and degradation of HIF. Asparagine hydroxylation by the factor inhibiting HIF 
(FIH) leads under normoxia to suppressed HIF transactivation. According to the model, 
proline and asparagine hydroxylation reactions are inhibited under hypoxia. 
 
In paper I, we established a mechanism that allows us to explain the molecular switch of the 
aryl hydrocarbon receptor (AhR) from its transcription factor to its E3 ubiquitin ligase 
function. We used the breast cancer cell line MCF7 to demonstrate that the availability of 
ARNT modulates the dual functions of AhR. Upon ARNT availability, the AhR functions as 
a ligand-induced transcription factor. If, however, other binding partners, such as the 
repressor of AhR (AhRR), occupy ARNT, the AhR functions as an E3 ubiquitin ligase. In 
paper II, we revealed significantly elevated FIH expression in skeletal muscle compared to 
other tissues. We also demonstrated that FIH loss leads to an induced oxidative metabolism, 
and an increased glycolytic capacity, resulting in elevated oxygen consumption. Loss of FIH 
further correlates with a decreased metabolic efficiency, an increased oxidative rate and an 
accelerated HIF-mediated response to hypoxia. In paper III (manuscript), we investigated 
the role FIH plays in epigenetic regulation, among others to explain the underlying 
mechanism behind the results presented in paper II. Muscle cells show the highest FIH levels 
on tissue level and we observed elevated histone 3 lysine 9 dimethyl (H3K9me2) levels in 
FIH null mice. Further work showed significantly increased methylation levels at the H3K9 
dimethyl repression mark at promoter regions of various metabolic HIF target genes in FIH 
null mouse embryonic fibroblasts, and subsequently correlations of loss of FIH and Jmjd1a 
dysregulated protein levels. In the following, despite promising preliminary results to date no 
FIH-Jmjd1a protein-protein interaction could be demonstrated. 
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1   INTRODUCTION  
Regulation of gene expression is a complex process that serves to initiate a response to 
changes in the cellular environment. Critical for the response in this regulatory network are 
DNA-binding transcription factors. Babu and colleagues use Pfam and SUPERFAMILY to 
predict the number of DNA-binding transcription factors to be around 2.600 (Babu MM, 
2004). E.coli research provides the most detailed information about an organism’s 
transcriptional network. In E.coli, around 75% of transcription factors are two-domain 
proteins, consisting of a regulatory and a DNA-binding domain, and around one third of the 
total transcription factors are expressed to regulate other transcription factors (Babu MM and 
Teichmann SA, 2003). Mammalian basic HLH (helix-loop-helix)-PER-ARNT-SIM (bHLH-
PAS) proteins shape a subclass of the bHLH superfamily (Fig. 1). The signal-regulated 
subunit dimerizes with the unregulated subunit and binds to specific DNA binding sites 
(motif of 4-6 DNA-binding basic amino acids) to trigger a specific response (Bersten DC, 
2013). 
 
             
 
Figure 1: Schematic representation of bHLH-PAS proteins with functional domains (Kewley 
RJ, 2004). 
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1.1   Aryl  hydrocarbon  receptor  
1.1.1   AhR  biology  
Aryl hydrocarbon receptor (AhR) is a member of the bHLH-PAS proteins. AhR gets induced 
by endogenous factors and a wide range of xenobiotic substances (Bersten DC, 2013; 
Denison MS, 2011). These can be divided into plant material or pollutants, including natural 
pollutants such as combustion-derived polycyclic aromatic hydrocarbon benzo(a)pyrene 
B(a)P, or synthetic pollutants such as hologenated aromatic hydrocarbons, for example, 
polychlorinated biphenyls (PCBs) or 2,3,7,8-Tetrachlorodibenzodioxin (TCDD). 
Upon ligand binding (Fig. 2), the chaperone-bound AhR translocates to the nucleus to 
dimerize with its dimerization partner aryl hydrocarbon receptor nuclear translocator 
(ARNT). The AhR-ARNT heterodimer binds to a xenobiotic response element (XRE) to 
induce transcription of classic detoxification pathway genes for phase I or phase II of 
xenobiotic metabolism, for example, AhR target gene cytochrome P4501A1 (CYP1A1) 
(Bersten DC, 2013). AhR null mice develop colonic and intestinal tumors, suggesting a tumor 
suppressor function of the receptor (Kawajiri K, 2009). 
 
         
Figure 2: Schematic representation of the AhR signaling pathway. Upon ligand-binding, 
AhR translocates into the nucleus, binds its dimerization partner ARNT, binds to XREs and 
triggers the expression of AhR target genes (Kewley RJ, 2004). 
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Another bHLH-PAS protein is the repressor of AhR (AhRR). The protein lacks the AhR-
specific transactivation and ligand-binding domain. For this reason, the AhRR cannot be 
induced by ligands (Mimura J, 1999). AhR and AhRR competitively utilize ARNT as 
dimerization partner protein. Oshima and coworkers demonstrated that mutual sumoylation 
increases AhRR-ARNT interaction and by XRE binding suppresses AhR signaling (Oshima 
M, 2009). In contrast, hypoxia inducible factor (HIF) – another dimerization partner of 
ARNT – is not affected by AhRR, as our studies show no effect on HIF target gene 
expression upon AhRR overexpression, indicating that AhRR does not suppress the HIF 
signaling pathway (Paper I). 
 
1.1.2   ARNT  
ARNT is a nuclear localized protein that serves as dimerization partner for bHLH-PAS 
family proteins (Eguchi H, 1997). It contains an N-terminal nuclear localization sequence 
(NLS), a heterodimerization domain and a C-terminal transactivation domain (Whitelaw ML, 
1994). Through its NLS, it binds to components of the nuclear pore (Kewley RJ, 2004). In 
contrast to its signal-regulated dimerization partner, ARNT protein is free from any 
repressive activity (Whitelaw ML, 1994). ARNT expression was found to be ubiquitous 
(Abbott BD and Probst MR, 1995). 
ARNT is an essential physiological factor. ARNT-/- studies demonstrated its importance in 
hypoxic regulation by dimerizing with HIF and help initiate transcriptional activation. ARNT-
/- mice show embryonic lethality due to abnormal vascular development (Maltepe E, 1997). 
Furthermore, knock-out studies showed the importance of ARNT during development and in 
physiology (Kozak KR, 1997; Wang XL, 2009). Ablation of ARNT caused an inaccurate 
hypoxic response and mouse embryos to die beyond embryonic day 10.5, as a consequence to 
defects in vascularization (Kozak KR, 1997). A liver-specific ARNT knock-out showed a 
metabolic phenotype similar to type 2 diabetes, including increased hepatic gluconeogenesis, 
increased lipogenic gene expression and low serum b-hydroxybutyrate (Wang XL, 2009). 
In addition to its well established role as bHLH-PAS dimerization partner, ARNT might have 
additional roles. ARNT’s preferred binding sequence CACGTG as well as its C-terminal 
transactivation domain might lead to activation of transcription by the CACGTG E-box 
(Antonsson C, 1995; Huffman JL, 2001). 
 
1.1.3   Breast  cancer  
Cancer is a complex disease. Abnormal cells divide in an uncontrolled manner, invade nearby 
tissues and reach through the blood/lymph system other parts of the organism. Tumors show 
heterogeneous gene expression, histology and clinical outcome. Hanahan and Weinberg 
described several factors with impact on tumor development (Hanahan D and Weinberg RA, 
2000; Hanahan D and Weinberg RA, 2011): 
-   Self-sufficiency in growth signals 
-   Insensitivity to anti-growth signals 
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-   Evasion of apoptosis 
-   Unlimited replicative potential 
-   Constant angiogenesis 
-   Tissue invasion 
-   Metastasis 
-   Cancer-specific metabolism 
-   Immune evasion 
-   Genomic instability 
-   Tumor-promoting inflammation 
In the case of breast cancer, new and malignant growth of tissue (neoplasm) arises in the 
ducts and lobules of the breast, consequently leading to metastasis in lung, bone and liver 
(Weigelt B, 2005). 
 
1.1.4   Breast  cancer  mortality  
Cancer is among the leading causes of death worldwide, despite a declining trend. According 
to the 2018 report of the American Cancer Society, breast cancer is the most frequently 
diagnosed cancer in women in the United States with over 266.000 estimated new cases. 
After lung cancer, breast cancer is the second major cause of death (14%). Before the age of 
20, brain tumors represent the leading cause of death, breast cancer between 20-59 years of 
age, and lung cancer thereafter. The 5-year relative survival rate for female breast cancer lies 
at 90%. The overall breast cancer death rate among women dropped 39% from 1989 to 2015 
(Siegel RL, 2018). In line with the US prognosis, the predicted number of deaths for women 
with breast cancer in 2018 in the European Union are the second highest after lung cancer 
(Malvezzi M, 2018). 
 
 
1.2   Hypoxia  inducible  factor  
1.2.1   Oxygen  
Energy for animal life is supplied by oxidation/reduction reactions that are coupled to ATP 
synthesis. Oxygen (O2) is the only molecule to serve as oxidant in these energy-producing 
reactions and its deprivation leads to rapid cell death. Due to varied energy requirements in 
cells, the demand for O2 varies remarkably among tissues. Oxygen can be incorporated into 
amino acids, fat, carbohydrates and other molecules, suggesting an important role of oxygen 
in the organism’s structure and regulation (Vanderkooi JM, 1991). In physiology, the amount 
of oxygen in a tissue is expressed in terms of its partial pressure (Po2), for example as 
millimeters of mercury (mmHg). There is no simple way to transform units of pressure to 
units of concentration as oxygen concentration depends on its solubility in a given fluid at a 
particular temperature and an ambient pressure of gas. 
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1.2.2   Hypoxia  inducible  factors  
Hypoxia inducible factor proteins are the master regulators of the hypoxic response (low 
oxygen). HIFs respond to oxygen changes, as they are regulated by two different oxygen-
dependent post transcriptional hydroxylations – hydroxylations of a proline and an 
asparagine. The three proline hydroxylases (PHD1, PHD2, PHD3) act at the oxygen-
dependent-degradation domain (ODD) and lead to binding of HIF to the von Hippel Lindau 
protein (pVHL). HIF binding to VHL results in polyubiquitination and degradation of HIF at 
the 26S proteasome. Asparagine hydroxylation controls HIF activity. HIF contains two 
transactivation domains (TADs) – the N-terminal (NTAD) and the C-terminal TAD (CTAD) 
(Ema M, 1999). Factor inhibiting HIF (FIH) causes an additional oxygen-dependent 
hydroxylation reaction, at the CTAD. FIH hydroxylates an asparagine within the HIF CTAD. 
This reaction prevents binding of the essential p300/CBP coactivators, resulting in a 
repressed CTAD. Proline and asparagine hydroxylation reactions require oxygen, hence, 
cellular hypoxia inhibits the reactions and results in stabilization of the HIF proteins, which 
results in recruitment of coactivators and activation of HIF target gene expression (Hewitson 
KS, 2002). As PHDs show in vitro lower affinity for O2 than FIH, it is suggested that the 
proline and asparagine hydroxylations generate a graded, coordinated response to hypoxia 
(Koivunen P, 2004). This has led to the view that during (Schofield CJ and Ratcliffe PJ, 
2005): 
-­‐   Moderate hypoxia: PHDs are inhibited, thus the NTAD is active and can activate HIF 
target gene expression  
-­‐   Severe hypoxia: FIH is inhibited as well, thus the CTAD is active and HIF target gene 
expression is fully activated.    
For HIF however, hydroxylation effects are well-characterized, causing repression of HIF-a 
activity in normoxia, whereas in hypoxia, when FIH is inhibited, HIF-a is potently activated 
and can drive expression of hundreds of target genes. 
 
1.2.3   HIF  response  
HIF-a proteins are members of the bHLH-PAS superfamily of transcription factors and 
regulate the cellular response to hypoxia. HIFs are degraded and repressed in normoxia, and 
stabilized and activated in hypoxia (Fig. 3). Upon stabilization, HIFs form DNA-binding 
heterodimers with their dimerization partner protein ARNT. HIFs bind to the consensus DNA 
sequence 5’-RCGTG-3’ within hypoxia responsive DNA elements (HREs) in numerous 
target gene promoters, and activate their transcription. The gene products help cells and 
animals adapt to hypoxia and include vascular endothelial growth factor (vascularization), red 
blood cell production (erythropoiesis) and numerous glycolytic enzymes (anaerobic ATP 
generation) (Fedele AO, 2002). 
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Figure 3: Schematic representation of the HIF signaling pathway. Upon lack of oxygen, 
HIFs translocate into the nucleus, bind their dimerization partner ARNT, bind to HREs and 
trigger the expression of HIF target genes (Kewley RJ, 2004). 
 
1.2.4   HIF-­a  isoforms  
HIF-a has several isoforms – HIF-1a, HIF-2a and HIF-3a. HIF-1a and HIF-2a have tissue-
specific roles. Both isoforms represent the signal-regulated and tissue-restricted subunit and 
dimerize with the more ubiquitous and unregulated subunit, known as HIF1ß or ARNT. HIF-
1a is ubiquitously expressed, but post-translationally degraded/inactive and upregulated in 
response to acute hypoxia to drive expression of mainly metabolic target genes. HIF-2a, on 
the other hand, shows a more restricted tissue distribution and drives target gene expression 
in response to chronic hypoxia. Besides its metabolic effects and the control of 
erythropoietin, HIF-2a has been shown to target antioxidant enzymes such as superoxide 
dismutase 1 and 2, glutathione peroxidase 1 and catalase (Scortegagna M, 2003). The 
expression of an alternative HIF-3a splice variant (iPAS) functions as negative regulator of 
HIF-1a and adds another level of complexity to the modes of HIF suppression (Makino Y, 
2001). 
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1.2.5   HIF’s  role  in  cancer  
HIFs are generally upregulated in a broad range of human cancers. HIF has effects on tumor 
growth and vascularization, and thus patient survival (Keith B, 2012). However, despite 
HIF’s well established tumor promoting effects, in certain contexts HIFs counterintuitively 
suppress tumor progression. Multiple HIF target genes play key roles in cancer biology, 
including metabolic reprogramming by targeting among others Aldolase 1, carbonic 
anhydrase 9 (CA9), phosphoglycerate kinase 1 (PGK1), or Enolase 1 (Semenza GL, 2012). 
In breast cancer cells, HIF-1a and HIF-2a levels are elevated and correlated to mortality 
(Bos R, 2003; Helczynska K, 2008). Liao and colleagues demonstrated that HIF-1a through 
its transcriptional activity positively promotes tumor progression and lung metastasis (Liao 
D, 2007). Metastasis accounts for nearly all breast cancer deaths (Talmadge JE, 2010). 
Intravasation and extravasation are central processes for breast cancer cells to metastasize, 
meaning breast cancer cells need to migrate from the primary tumor into a blood vessel and 
afterwards migrate into a distant metastatic site, for example, the lungs. The HIF target 
vascular endothelial growth factor (VEGF) has been shown to promote the effects of 
intravasation (Sullivan R and Graham CH, 2007). 
Furthermore, it has been shown that HIFs regulate two critical steps required for 
extravasation – margination and disruption of the tight interactions between endothelial cells 
(Padua D, 2008; Zhang H, 2012). Margination describes the process of cancer cells adhering 
to endothelial cells in the lung vasculature. Zhang and colleagues showed HIF-1a (not HIF-
2a)-induced L1 cell adhesion molecule (L1CAM) expression in hypoxic breast cancer cells 
leads to increased lung metastasis via elevated interaction of breast cancer cells with 
endothelial cells, which results in margination and consequently extravasation (Zhang H, 
2012). To conclude HIFs function as facilitator of breast cancer cell migration from its 
primary to its metastatic site, hypoxia also regulates cell motility and permeability. Padua and 
colleagues identified angiopoietin-like 4, a hypoxia-dependent (HIF-1a and HIF-2a) protein 
that inhibits interactions between endothelial cells and has a demonstrated history in 
modulating vascular permeability, cancer cell motility and invasiveness. Breast cancer 
patients with lung metastases show elevated expression levels of angiopoietin-like 4 (Kim 
SH, 2011; Padua D, 2008). 
 
1.2.6   Interaction  between  signaling  pathways  
Signaling pathways are connected on different levels. Recent work discovered interactions of 
hypoxia, HIFs and oxygen-sensing enzymes with numerous pathways of central function in 
physiology and disease. The following examples aim to showcase this widespread interaction 
(Gustafsson MV, 2005; Rodriguez J, 2018; Shareef MM, 2013; Yin G, 2017): 
 
1. Tumor suppressor p53 (Rodriguez J, 2018) 
Regulation of p53 tumor suppressor through hypoxia and hydroxylase inhibition has been 
subject to speculation for a long while. Recent work from Rodriguez and colleagues 
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demonstrated that PHD3 hydroxylates p53 at proline 359, which is located in the p53-DUB 
binding domain. The removal of ubiquitin chains is mediated by USP7 and USP10, two 
deubiquitinating enzymes (DUBs). P359 hydroxylation decreases p53-USP7/USP10 
association, and consequently elevates p53 ubiquitination, which leads to reduced p53 levels. 
The authors conclude to have identified p53 as novel PHD3 substrate and uncovered a direct 
mechanism of post-translational modification through the oxygen-sensing enzyme to regulate 
p53 protein stability (Rodriguez J, 2018).  
 
2. Notch (Gustafsson MV, 2005; Shareef MM, 2013) 
Gustafsson and colleagues were the first to report interactions between the cellular hypoxic 
response and Notch signaling (Gustafsson MV, 2005). Notch signaling is conserved across 
metazoan species. In Notch signaling, the pathway is initiated upon cell-cell-contact. A Notch 
(Notch1-4) transmembrane receptor-presenting cell is activated by a Notch ligand-presenting 
cell (DSL including Delta-like and Jagged). Interaction with ligand leads to successive 
cleavage events, eventually liberating the Notch intracellular domain (NICD) from the 
plasma membrane. The NICD translocates into the nucleus, recruits a transcriptional 
activation complex with the DNA-binding protein CSL and co-activators and finally activates 
transcription of downstream Notch target genes (Bray SJ, 2006; Poellinger L and Lendahl U, 
2008). Shareef and colleagues further demonstrated that HIF-1a and Notch 3 (and VHL) 
interaction is required at the carbonic anhydrase 9 (CA9) promoter for the expression of CA9 
in breast cancer carcinoma cells (Shareef MM, 2013). 
 
3. Lipid metabolism (Yin G, 2017) 
Metabolic switches allow cells to adapt to different conditions. Hypoxia is an example for 
such an alteration in environmental condition. While oxidative phosphorylation represents the 
major source of ATP production in most mammalian cells in normal conditions, during 
hypoxia, cells decrease their mitochondrial oxygen consumption and among others induce 
lipid metabolism (Strehl C, 2014). In mammalian cells, the serine/threonine kinase rapamycin 
(mTOR) is central in sensing of extracellular stimulations and mediating intracellular 
adaptations (Ricoult SJ, 2013). Yin and colleagues identified mTOR as key player that allows 
regulation of lipid homeostasis in lymphocytes by mediating the switch from lipid synthesis 
to lipid oxidation during hypoxia (Yin G, 2017).   
 
 
1.3   Factor  inhibiting  HIF  
1.3.1   Factor  inhibiting  HIF  hydroxylates  ARD-­containing  proteins  
Factor inhibiting HIF (FIH) was originally discovered as an inhibitor of the HIF-a proteins 
(Mahon PC, 2001). The transcriptional activity of HIFs is partly determined by asparaginyl 
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hydroxylation (Asn803) by FIH of a C-terminal residue that regulates co-activator 
recruitment (Lando D, 2002). Hydroxylation of HIFs by FIH inhibits transcriptional 
activation by blocking association of HIFs with the transcriptional co-activators CBP/p300 
(Kallio PJ, 1998). FIH utilizes O2 and 2-oxoglutarate and contains Fe (II) in its active site 
(Lando D, 2002). FIH hydroxylates ARD-containing proteins, such as Notch (Coleman ML, 
2007; Cockman ME, 2009). Since ARDs are ubiquitous (>5% of eukaryotic proteins), post-
translational modification by hydroxylation via FIH seems to be very common in human cells 
(Kelly L, 2009). 
 
FIH has ubiquitous function in physiology and disease. Three examples are given below 
(Janke K, 2013; Liu Y, 2013; Peng H, 2013): 
 
1. FIH hydroxylation causes changes in protein-protein interaction (Janke K, 2013) 
Protein interactions of ARD-containing substrates can be modified by FIH-dependent 
hydroxylation. Janke and colleagues identified apoptosis-stimulating p53-binding protein 
(ASPP) as FIH target. ASPP2 has a single hydroxylation site (N986) located within the ARD. 
While ASPP2 protein levels and stability were not affected by depletion or inhibition of FIH, 
ASPP2 binding to Par-3 (cell polarity) was impaired. Furthermore, the study shows relocation 
of ASPP2 from cell-cell contacts to the cytosol in FIH depleted colon carcinoma cells. 
Despite the finding that FIH had no effect on ASPP-p53-interaction, apoptosis, or 
proliferation of cancer cells, it suggests an important role of FIH hydroxylation on protein-
protein interaction. 
 
2. FIH-c-kit interaction regulate glycogen metabolism (Peng H, 2013) 
Stem cell factor (STF) serves as ligand for tyrosine kinase receptor c-kit. STF-mediated c-kit 
activation regulates cancer-associated protein kinase B (Akt). Peng and colleagues identified 
FIH-c-kit interaction as mediator of glycogen metabolism in corneal epithelial keratinocytes 
and showed diminished glycogen stores through the Akt/Glycogen Synthase Kinase (GSK-
3beta) pathway. c-kit targets glucose metabolism via the Akt/GSK-3beta, which is further 
increased through FIH-c-kit interaction by activating GSK-3beta, resulting in inhibition of 
glycogen synthase/synthesis. 
 
3. Increased vascularization as result of sequestered FIH (Liu Y, 2013) 
Gankyrin is an oncoprotein overexpressed in hepatocellular carcinomas that contains seven 
ankyrin repeats, which are interacting with multiple proteins such as Cdk4, Mdm2, NF-kB, 
and Rb. Liu and colleagues demonstrated that transgenic mice overexpressing gankyrin 
developed hepatic vascular neoplasms. Liu et al. further showed that gankyrin binds to and 
sequesters FIH, which lead to decreased FIH-HIF-interaction and increased activity of HIF 
on the VEGF promoter. These effects of gankyrin are more prominent under 3% than 1% O2. 
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1.3.2   FIH  –  a  JmjC  domain-­containing  hydroxylase  
JmjC domain-containing proteins play a crucial role in the control of gene expression by 
acting as protein hydroxylases or demethylases. Trewick and colleagues claimed that the 
fission yeast protein Epe1 is a putative histone demethylase. Similar to FIH, Epe1 contains a 
JmjC domain (Trewick SC, 2005). Recent work has demonstrated that other 2OG oxygenases 
(similar to FIH) catalyze histone demethylation (Loenarz C and Schofield CJ, 2011). Another 
JmjC domain-containing enzyme, Jmjd6, has been shown to act as a histone arginine 
demethylase as well as a lysine hydroxylase (Chang B, 2007; Webby CJ, 2009). It appears 
plausible that, in addition to the established oxygen-dependent regulation of HIF function via 
HIF hydroxylases, there are other targets and steps in the hypoxia signaling pathways that are 
controlled by other 2-oxoglutarate oxygenases, such as FIH. 
 
1.3.3   FIH  knock-­out  
Mice lacking FIH show no alteration of classical HIF function, such as angiogenesis, or 
erythropoiesis. Rather, it causes a hypermetabolic phenotype, including reduced body weight, 
hyperventilation, elevated metabolic rate, and improved glucose and lipid homeostasis. 
Furthermore, these mice are more resistant to weight gain and hepatic steatosis induced by a 
high fat diet. A conditional neuron-specific knock-out shows lack of FIH results in reduced 
body weight, an increased metabolic rate, increased insulin sensitivity and resistance to high-
fat-diet induced weight gain (Zhang N, 2010). 
 
1.3.4   Role  in  disease  
FIH is ubiquitously expressed, predominantly cytoplasmic but, in most normal tissues, with 
significant amounts detectable in the nucleus (Metzen E, 2003; Soilleux EJ, 2005). In tumor 
cells, however, it more often adopts an exclusively nuclear localization and, furthermore, its 
subcellular localization has been correlated with patient survival (Kroeze SG, 2010; Shaida 
N, 2011; Soilleux EJ, 2005; Tan EY, 2007). It has been reported for breast and renal tumors 
that high levels of nuclear FIH predict longer patient survival, whereas the lack of nuclear 
localized FIH predicts a more adverse outcome (Kroeze SG, 2010; Shaida N, 2011; Tan EY, 
2007). On the other hand, in prostate tumors, the trend is the opposite (Kroeze SG, 2010; 
Shaida N, 2011; Tan EY, 2007). The mechanism for these correlates is unknown and whether 
FIH acts causally or purely as a silent marker is also not known. 
 
 
1.4   Epigenetics  
Regulation of gene expression has evolved from characterizing transcription factors and their 
binding sites into a complex collection of post-transcriptional events, including microRNA, 
DNA methylation, or histone modifications that package DNA. 
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1.4.1   Chromatin  
Histones are nucleoproteins in eukaryotic cells. Their net positive charge allows them to 
associate with negatively charged core DNA to help condense it into chromatin. They 
package and order DNA into structural subunits called nucleosomes (Bernstein BE, 2007). 
Nucleosomes form a pack called chromatin (two chromatins form a chromosome) and consist 
of the following histone types: H2A, H2B, H3, and H4. H1 serves as nucleosome connector 
and represents the least tightly bound histone to chromatin. Nucleosomes are the first level of 
DNA organization and consist of two copies of four core histones (H2A, H2B, H3, H4), 
called octamer. 146 base pairs (bp) DNA are wrapped around one histone octamer. Linker or 
spacer DNA (8-114bp) connect histone octamers (Kornberg RD and Lorch Y, 1999; 
Richmond TJ and Davey CA, 2003). 
 
1.4.2   Chromatin  modification  
In addition to sequence-specific activators and repressors, chromatin modification and 
remodeling play crucial roles in regulation of gene expression. Residues within the histone 
tails and the histone globular domains can be modified in various ways, including 
phosphorylation, acetylation, ubiquitination, and methylation (Lee JS, 2010). Histone 
modifications have context-dependent effects and can act in multiple ways (Fig. 4). 
 
               Figure 4: Schematic representation of histone modifications (biochem.slu.edu/). 
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According to Suganuma and colleagues three main cross-regulatory mechanisms appear to 
exist (Suganuma T, 2008): 
(1)  A histone modification initiates an increased activity in a histone-modifying enzyme, 
(2)  Coordination of different histone-modifying enzymes present in the same protein 
complex, and 
(3)  A histone modification mediates the cleavage of the N-terminal tail of histone H3, 
leading to an irreversible modification. 
For example, it has been shown that H2B ubiquitination is required for histone 3 lysine 4 
methylation by H3K4 methylase complex COMPASS (complex of proteins associated with 
Set-1) (Shilatifard A, 2006). To add another level of complexity, deubiquitination also affects 
histone 3 methylation, hence, H2B ubiquitination and deubiquitination act as master switches, 
mediating numerous histone 3 methylation events (Wyce A, 2007). 
These depending scenarios can be facilitated through complexes histone-modifying enzymes 
bind to, therefore modification of specific binding sites may lead to access of another enzyme 
to a nearby residue. This interplay can lead to facilitation or prevention of recognition of 
another substrate (Guccione E, 2007; Martin DG, 2006). 
 
1.4.3   Chromatin  modifying  enzymes  
Histone modifications influence central cellular events by regulating chromatin structure and 
gene transcriptional activity. The different modifications are correlated to either 
transcriptional activation or repression. Numerous enzymes control these modifications in a 
dynamic manner to add and remove these modifications. 
Jumonji Domain Containing 1A (Jmjd1a; also known as JMJD2A/KDM4A) is a histone 
lysine demethylase that targets H3K9 and H3K36 (Berry WL and Janknecht R, 2013). 
Jmjd1a specifically targets H3K9me2 reactions, which is associated with transcriptional 
repression. Jmjd1a regulates metabolic genes related to energy homeostasis, including anti-
adipogenesis, fat storage, glucose transport, and type 2 diabetes. The histone demethylase 
plays further an important role in DNA damage response, cellular differentiation, and male 
germ cell development and nuclear hormone receptor-mediated gene activation (Berry WL 
and Janknecht R, 2013). Furthermore, studies have shown that Jmjd1a is overexpressed in 
tumors, among others breast, colorectal, lung, and prostate cancer, and that it is required for 
efficient cancer cell growth (Guerra-Calderas L, 2015). 
Jmjd1a mouse knockout models identify the histone demethylase as an important regulator of 
the expression of metabolic genes. Tateishi and colleagues demonstrated ablation of Jmjd1a 
results in obesity and hyperlipidemia in adult mice by disrupting beta-adrenergic-stimulated 
glycerol release and oxygen consumption in brown fat, decreasing fat oxidation, and 
diminishing glycerol release in skeletal muscles. The authors demonstrated peroxisome 
proliferator-activated receptor alpha (PPARa) and uncoupling protein 1 (UCP1) – genes 
involved in controlling energy balance – are regulated and therefore direct targets of Jmjd1a. 
This was achieved by decreased levels of H3K9me2 at the PPAR responsive element (PPRE) 
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in response to beta-adrenergic activation-induced binding of Jmjd1a to PPRE of the ucp1 
gene (Tateishi K, 2009).  
Tateishi and colleagues’ findings are in line with a study conducted by Inagaki et al. They 
identified Jmjd1a as overall crucial for regulating the expression of metabolic genes related to 
energy homeostasis including anti-adipogenesis, regulation of fat storage, glucose transport, 
and type 2 diabetes. Loss of Jmjd1a function phenotypically results in adult onset obesity, 
hypertriglyceridemia, hypercholesterolemia, hyperinsulinemia, and hyperleptinemia – 
hallmarks of the metabolic syndrome – and fasted-induced hypothermia indicating reduced 
energy expenditure, as well as a higher respiratory quotient indicating less fat utilization for 
energy production. Inagaki and colleagues also observed suppressed global H3K9 
demethylation and germ cell developmental defect in males due to ablation of Jmjd1a 
(Inagaki T, 2009).  
Furthermore, Okada and colleagues identified Jmjd1a as essential factor in spermatogenesis, 
in the regulation of fat metabolic gene expression in muscle and brown fat tissue, and in 
obesity and hyperlipidemia. Infertility is achieved by impaired postmeiotic chromatin 
condensation through direct binding of Jmjd1a to core promoter regions of genes involved in 
sperm nuclear condensation (Okada Y, 2010). 
H3K9 methylation is a pivotal epigenetic mark known to be transcriptional repressing. 
Hypoxia increases global H3K9me2 levels, which results in elevated histone 
methyltransferase G9a protein expression and enzyme activity (Chen H, 2006). G9a is a 
H3K9 specific methyl transferase and essential for embryonic development (Tachibana M, 
2002). Tachibana and colleagues further identified a related methyltransferase, the G9a-like 
protein (GLP), to be important for H3K9 methylation of mouse chromatin. GLP-deficiency 
led to severe decrease in H3K9me1/me2 levels and lethality in embryos. The authors 
conclude that G9a and GLP work cooperatively in complexes to function as a 
methyltransferase in vivo (Tachibana M, 2005). 
Inactive X-chromosomes are rich in histone 3 methylation at lysine 9 and lysine 27. Ohhata 
and colleagues therefore suggested a role of G9a in X-inactivation by studying the X-inactive 
specific transcript (Xist). Despite the absence of G9a, Xist is properly regulated and the X 
chromosome inactivated. The authors consequently conclude, ablation of G9a is not essential 
for X-inactivation (Ohhata T, 2004). Tachibana and colleagues, on the other hand, 
demonstrated dramatic effects of G9a ablation. Not only observed the authors drastically 
reduced H3K9 methylation levels mostly in euchromatin regions, but more importantly 
severe growth retardation and early lethality, implicating H3K9 methylation regulated by G9a 
has important roles in early embryogenesis through transcriptional repression of 
developmental genes (Tachibana M, 2002). 
 
1.4.4   Chromatin  and  HIF  
Hypoxia increases global H3K9me2 in several mammalian cell lines, which is correlated with 
an increase in histone methyltransferase G9a protein and enzyme activity (Chen H, 2006). 
Furthermore, it is proven that the histone demethylase genes Jmjd1a, Jmjd2b, and Jarid1b are 
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HIF targets, suggesting an indirect influence of HIFs on gene expression at the level of 
histone methylation under hypoxia (Krieg AJ, 2010). Epigenetic regulatory mechanisms play 
a crucial role in the cellular response to hypoxia. Modulation of the hypoxic response by 
epigenetic mechanisms seems to be multilayered (Watson JA, 2010): 
(I)   Stabilization of HIF proteins is influenced by epigenetically controlled expression 
of VHL and PHD3. 
(II)   Epigenetic modifications regulate HIF binding by inducing or maintaining an 
active chromatin confirmation within and around HIF binding site regions. 
(III)   HIF-1a targets the transcription of histone demethylases, such as Jmjd1a. 
(IV)   Global changes in histone modifications and DNA methylation occur in response 
to low oxygen levels. 
(V)   Nucleosome-free DNA regions (NFRs) are established while hypoxia-induced 
transcription takes place in hypoxia-inducible promoters (Suzuki N, 2018). 
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2   AIMS  
The main purpose of my PhD study was to elucidate mechanisms of gene regulation in 
response to external factors - specifically by the transcription factors HIF (oxygen) and AhR 
(toxins). In order to better understand HIF’s role in hypoxia-dependent transcriptional 
activation, we focused on the regulation of HIF signaling by the enzyme FIH. The specific 
aims of my thesis were to: 
 
1.   Identify the molecular mechanism that modulates the dual functions of AhR in breast 
cancer cells by analyzing the role of ARNT; 
2.   Characterize FIH’s role in regulation of the oxidative response and its role in 
accelerating metabolic adaptations to hypoxia in muscle cells; and 
3.   Unravel the mechanism of FIH action in an oxygen-dependent manner to induce an 
epigenetic response in muscle cells. 
 
 

  17 
3   RESULTS  AND  DISCUSSION  
3.1   Identification   of   a   molecular   switch   mechanism   shifting   the   aryl  
hydrocarbon  receptor  from  an  E3  ubiquitin  ligase  to  a  transcription  factor  
(Paper  I)  
 
The present study was carried out in order to describe a molecular mechanism that allows 
AhR to switch between its transcription factor and E3 ubiquitin ligase function. To date, 
AhR is the only bHLH-PAS protein identified to possess these dual functions. Central for 
the regulation of the switch process proved to be the ubiquitously expressed protein ARNT, 
which itself is regulated by the bHLH-Pas protein AhRR. Follow-up work with AhRR 
overexpression resulted in reduced tumor mass, arguing for a tumor-suppressive-like 
function of AhR. 
 
ERα degradation by the CUL4BAhR complex is not dependent on ARNT.  
 
We chose MCF7 cells to study the transcription factor versus proteasomal degradation 
function of AhR, as this specific human breast cancer cell line expresses a functional ERα 
signaling pathway. Our initial experiments showed that the AhR functions as a ligand-
activated E3 ubiquitin ligase targeting ERα for proteasomal degradation by using 
immunoprecipitation and RNA interference assays. As demonstrated before, AhR protein 
itself was degraded upon ligand treatment (Davarinos NA, 1999). Ablation of ARNT in 
TCDD treated MCF7 cells resulted in significantly decreased ERα (higher levels of 
ubiquitinated ERα) and CYP1A1 levels, indicating that the ubiquitously expressed 
dimerization partner of AhR is critical for AhR’s transcription factor function. 
In previous work by Ohtake and colleagues, ARNT has been identified as part of the 
Cul4bAhr transcription complex along with Cullin-4B, Rbx1, DDB1, TBL3, the 19S 
regulatory particle, and activated AhR (Ohtake F, 2007). In contrast to Ohtake’s findings, 
we could not identify ARNT as part of this multi-component complex upon TCDD 
treatment (Co-IP with Cul4B antibody). However, while we used Flag-tagged ARNT in 
MCF7 cells and neither found ARNT nor Cul4B or ERα as complex components, Ohtake 
and colleagues used Flag-tagged AhR overexpressed in HeLa cells. We believe their 
conclusion might be the result of a detected mix of Cul4BAhR E3 ubiquitin ligase and AhR-
ARNT transcription factor complex, indicating their results show ARNT within the AhR-
ARNT transcription factor complex and not within the E3 ubiquitin ligase complex. 
 
 
Degradation of ligand-activated AhR is dependent on ARNT. 
 
AhR levels are subject to a tight control mechanism. Previous work by Ma and Baldwin 
showed that AhR when induced by ligands is regulated in a time- and dose-dependent way. 
Ma also showed that the ligand-induced ubiquitinylation of AhR is dependent on ARNT 
(Ma Q, 2000). We confirmed these data, indicating ARNT plays a central role in ligand-
activated AhR degradation. 
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DNA binding disruption of AhR and by that negative regulation of AhR 
transcriptional function in cells overexpressing AhRR. 
 
AhR and AhRR both operate by dimerizing with ARNT (Oshima M, 2009). To further 
analyze TCDD-induced AhR signaling, we developed stably overexpressing Myc-tagged 
AhRR MCF7 cells. We then examined the effect of overexpressed AhRR on CYP1A1 and 
found decreased expression levels and enzyme activity, and impaired AhR recruitment to 
the CYP1A1 XRE DNA binding site, indicating overexpression of AhRR show disrupted 
transactivation potential and DNA binding of ligand-induced AhR.  
 
 
MCF7 cells stably overexpressing AhRR show decreased estrogen responsiveness and 
ERα protein levels.  
 
To further investigate the role of AhRR in the process that allows AhR to switch between 
its dual functions, we next analyzed whether overexpression of AhRR: 
a)   changes the E3 ubiquitin ligase function of AhR, and 
b)   shows effects on estrogen treatment (AhR targets ERα for proteasomal degradation) 
Our results obtained show that AhRR overexpression leads to reduced ERα target gene 
levels (cathepsin D and progesterone receptor). Previous work by Brunnberg et al. 
identified ARNT as cofactor for estrogen-dependent transcription, opening up the 
possibility that coactivator competition might have an effect on the responsiveness of ERα 
target genes to estrogen treatment (Brunnberg S, 2003). The observation of decreased 
estrogen responsiveness was supported by the finding that ERα protein levels were lower 
and E3 ubiquitinylation was increased in cells overexpressing AhRR. AhRR-ARNT 
interaction, as previously shown by Oshima and colleagues, apparently (shown in our 
study) results in switching the AhR receptor towards its E3 ubiquitin ligase function 
(Oshima M, 2009). 
In conclusion, despite the potential effects AhRR overexpression might have on other 
signaling pathways that regulate ERα function, our data argue in favor of ARNT being the 
mediator of the molecular switch of AhR as transcription factor and E3 ligase. 
 
 
MCF7 xenograft tumors stably overexpressing AhRR show reduced tumor volume 
and ERα expression.  
 
The effect of AhR E3 ubiquitin ligase function on ERα protein levels may have therapeutic 
implications for the treatment of estrogen-dependent tumors, hence, we conducted an in 
vivo study to investigate tumor growth in MCF7 breast cancer cells with high levels of 
AhRR. AhRR overexpressing MCF7 cells show significantly lower proliferation rates, as 
previously described by Zhang and colleagues in estrogen-dependent cell lines (Zhang S, 
2009). The estrogen-independent cell line MDA-MB-468 on the other hand showed no 
effect on cell proliferation. Our xenograft studies show decreased ERα protein levels 
(similar to our in vitro data) and a reduction of tumor growth in SCID mice that received 
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AhRR overexpressing cells, indicating a tumor-suppressive role of AhR in MCF7 xenograft 
tumors. Again, our data clearly point towards a tumor-suppressive function of AhR. Recent 
literature argues in favor and against these findings. While AhR was identified to possess 
protumorigenic function in liver and stomach tumors, Kawajiri and colleagues suggest an 
antitumorigenic role of AhR (Andersson P, 2002; Kawajiri K, 2009; Moennikes O, 2004). 
Standard cancer therapy includes surgery, radiation therapy, hormone therapy, and 
chemotherapy – often used in combination. Hormone-dependent tumors, for example, 
breast cancer, are widely subject to hormone therapies, including aromatase inhibitors 
(inhibiting E2 production) or estrogen receptor antagonists (e.g. tamoxifen). Resistance to 
these approaches represent a major obstacle in the treatment plan and might result in the 
development of a more aggressive phenotype. 
In summary, our data support a central role of ARNT in the modulation of the molecular 
switch of AhR towards its transcription factor or E3 ubiquitin ligase function targeting ERα 
for proteasomal degradation. The availability of ARNT seems to direct AhR towards one of 
its dual functions. In addition, we also show that AhRR overexpression in MCF7 cells 
results in reduced levels of ERα protein levels, reduced growth rates, and reduced estrogen-
dependent xenograft tumor growth, implying that AhRR protein levels modulate ARNT 
availability and thereby AhR function. Whether or not AhR E3 ubiquitin ligase function 
can be utilized for treatment of estrogen-dependent tumors, is unclear. It is certain, 
however, that our findings point towards a tumor-suppressor role of the E3 ubiquitin ligase 
function and there is a need for therapeutic treatment that targets the cellular levels of 
activated ERα. More in vivo data will shed light on the mechanisms around AhR and reveal 
its cancer therapeutic potential. 
 
 
 
3.2   Identification  of  the  factor  inhibiting  HIF  as  regulator  of  the  oxidative  
metabolism  and  driver  of  the  metabolic  response  to  hypoxia  (Paper  II)  
 
In the current study, we characterize the role of FIH as metabolic mediator in response to 
changes in energy demand in skeletal muscle. We further compared FIH and VHL function 
and show synergistic actions of these two key post-translational HIF regulators to modulate 
metabolism. 
 
Metabolic effects in FIH and VHL Null Cells 
We performed microarray analysis and showed that in contrast to loss of VHL loss of FIH 
can operate both as activator and suppressor of metabolic genes in MEFs under normoxic 
oxygen levels (deletion of both factors has distinct effects compared to their single deletions). 
The observed differences might be due to additional functions FIH has when HIF levels are 
low. The following differences were observed in an qRT-PCR approach: 
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-   Loss of VHL: decreases levels of oxidative genes and increases expression of most 
glycolytic genes under normoxia and early hypoxia 
-   Loss of FIH: increases levels of glycolytic gene expression and “locks” oxidative 
gene expression under normoxia and early hypoxia 
Next, we examined intracellular aqueous metabolites (lactate, alanine, glucose, and 
glutamine) and found clear differences in FIH null and control cells. The above findings are 
supported by previous studies that demonstrated an upregulation in glycolytic genes as a 
consequence of loss of FIH (Sakamoto T, 2011; Wang E, 2014). 
 
FIH modulates mitochondrial activity 
Several observations in the present study point towards a function of FIH in regulating 
mitochondrial activity. The following findings support this conclusion: 
1.   Metabolic differences in FIH and VHL Null Cells 
Due to its high affinity to oxygen, FIH can act as a modulator of the hypoxic response 
at low oxygen levels. For example, FIH null MEFs showed elevated lactate production 
and glucose uptake during prolonged hypoxic conditioning but not during normoxia. 
Interestingly, ATP levels were elevated under 21% O2, arguing in favor of the presence 
of alternative oxygen-dependent pathways, possibly as a result of the formation of 
metabolic intermediates activated by loss of FIH. Data from VHL null MEFs (elevated 
ATP levels) support a correlative function of these two post-translational HIF 
regulators. 
 
2.   FIH suppresses production of hypoxia-induced mitochondrial ROS 
Furthermore, FIH loss does not alter mitochondrial superoxide production at normal 
oxygen levels. Previous findings by Rasbach and colleagues show regulation of 
superoxide dismutase by HIF-2a, which contributes to the control of the antioxidant 
defence mechanism and limits the production of reactive oxygen species (ROS) 
(Rankin EB, 2007; Rasbach KA, 2010). In the current study, we demonstrate prolonged 
hypoxia generated an increase in ROS production in wild-type cells, which is 
suppressed by loss of FIH – another indication that native FIH activity is not totally 
suppressed at low oxygen levels. 
 
3.   No effect of loss of FIH on the mitochondrial membrane potential 
The data generated until this stage allows the conclusion that the roles of VHL and FIH 
in mitochondrial regulation are clearly differential. While FIH mediates mitochondrial 
ROS production and apoptosis in hypoxia, VHL does so in normoxia. We further 
showed that lack of VHL diminished mitochondrial membrane potential in normoxia. 
In contrast, loss of FIH shows no effect on mitochondrial potential in 
normoxia/hypoxia. 
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4.   Mitochondrial levels and activity of FIH null MEFs 
Further studies demonstrated that lack of FIH stimulate the hypoxic effects on 
mitochondria, indicating diminished mitochondrial functioning and stimulating a shift 
to a glycolytic metabolism. Loss of FIH increases cytochrome c oxidase (COX) activity 
in normoxia, while chronic hypoxic O2 levels reduce COX activity again, suggesting 
loss of FIH plays a role in oxidative metabolism. 
 
FIH effects on glycolytic metabolism and oxygen consumption 
In order to gain further insights into a better understanding of the metabolic response in the 
knock-out MEFs, we studied oxygen consumption and proton generation in these cells under 
normoxic oxygen levels. 
Loss of FIH showed a significantly elevated glycolytic reserve in normoxia, suggesting a sort 
of preparedness for hypoxic glycolytic metabolism. Loss of both FIH and VHL drives cells 
into an ultimate glycolytic state, meaning cells generate energy solely from glycolosis in 
contrast to oxidation. 
As shown in previous work by Hervouet and coworkers, VHL null MEFs show the predicted 
oxygen consumption response, meaning complete usage of the spare respiratory capacity 
(Hervouet E, 2005). In contrast to previous findings, FIH null cells, on the other hand, 
stimulate an increased basal respiration rate in normoxia, which is erased by chronic hypoxia, 
indicating a suppressive function of the hypoxic response (Fukuda R, 2007). The increased 
oxygen consumption in FIH null cells is not a result of a switch to fatty acid oxidation, but 
instead glucose is channeled through pyruvate to the mitochondria.  
 
FIH effects in skeletal muscle 
Loss of FIH in skeletal muscle reveals two main functions – acceleration of hypoxic 
metabolic shifts and stimulation of hypoxic adaptations. 
The data provided in this study clearly point towards a role for FIH as mediator of the 
response to rapid changes in tissue’s metabolic activity due to varying oxygenation status. 
Exclusively skeletal muscle show the by far highest FIH expression levels, both fast and slow 
twitch muscle. Our in vivo data were generated in global FIH deletion animals (global VHL 
deletion is postnatally mortal), as they show higher basal metabolic rates, as previously 
demonstrated by Zhang and coworkers, or skeletal muscle-specific deletions of FIH, VHL, or 
both (Zhang N, 2010). The following findings were observed: 
-   Loss of FIH: no shifts in basal metabolic rate, higher nocturnal VO2, increased VO2 in 
skeletal muscle during exercise 
-   Loss of VHL: higher nocturnal VCO2, decreased VO2 in skeletal muscle during 
exercise, increased myoglobin expression in skeletal muscle 
-   Loss of FIH/VHL: sharp fall-off in VO2 at higher running speeds, fiber type switch 
away from fast twitch towards slow twitch, which is a more oxidative fiber type 
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In sum, lack of FIH increases oxygen uptake, while lack of VHL suppresses it. Lack of 
FIH/VHL causes an accelerated response that drastically lowers oxidative metabolism. 
The maximal aerobic capacity (or maximal oxygen consumption; VO2 max) serves as key 
measure of an individual’s endurance capacity during sustained, prolonged exercise. Skeletal 
muscle-specific FIH knock-out cells show an increased oxygen dept after exercise, 
supporting the finding that FIH null cells have an elevated oxidative metabolism. We further 
showed that FIH null mutant mice have an increased maximum rate of oxygen consumption 
during incremental exercise compared to baseline VO2, and reach their VO2 max at a lower 
speed, indicating FIH null mutants maintain glycogen reserves to utilize at higher intensities. 
The diminished oxygen efficiency at low intensities seems to not have an effect on the overall 
long-distant running performance, as we observed no reduced endurance compared to the 
control mice (in contrast to VHL and FIH/VHL mutants). We further observed: 
-   Increased relative COX activity, 
-   Elevated overall perfusion of the FIH mutant muscle, 
-   Significantly increased serum lactate levels, 
-   Suppressed VO2 with increased exercise intensity, 
-   Decreased VO2 under lower oxygen levels (12%; inhalation), 
indicating an accelerated metabolic response that is characterized by elevated VO2 during 
early exercise and subsequent suppression of oxygen uptake shifting the aerobic into an 
anaerobic metabolism at higher exercise intensities. These hypoxic adaptations might explain 
the examined decrease in oxygen efficiency despite continued exercise performance. 
 
Conclusions drawn from our findings can picture the following model: lack of FIH 
accelerates oxidative processes > decreases intracellular oxygen levels > inhibits PHDs > 
accumulates HIF > suppresses oxidative metabolism via HIF. This model might be especially 
relevant for tissues that are subject to rapid changes in oxygen levels to keep the cells in an 
oxidative state for as long as possible and subsequently to quickly induce the shift to 
anaerobic metabolism through the accumulation of HIF. As shown in our study, skeletal 
muscle shows highest FIH protein levels. This is supported by previous findings that 
demonstrate elevated FIH expression levels in elite endurance athletes (Lindholm ME, 2014). 
To maintain an oxidative state, FIH might alternatively use other oxygen storages, for 
example, oxygen bound to myoglobin in the muscle cell surface (Takahashi E and Asano K, 
2002).  
This study sheds further light on FIH action, even though the mechanisms of action stay 
elusive. For example, we have not addressed the hydroxylase function of FIH, potential 
interactions via its JmjC domain, to which extent FIH function is dependent on oxygen and 
HIF, the spatial localization of FIH, or hypothetical non-HIF targets of FIH. Further studies 
will be needed to understand FIH action in more detail to unveil its relevance in physiology 
and disease. 
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3.3   The  asparagine  hydroxylase  factor  inhibiting  HIF  correlates  with  
epigenetic  changes  and  targets  the  histone  demethylase  Jmjd1a  
(Manuscript)  
 
FIH is a protein involved in the regulation of HIF-a (Mahon PC, 2001). The by far highest 
expression of FIH protein is found in skeletal muscle, indicating key regulatory roles the 
asparagine hydroxylase holds in this tissue (Zhang N, 2010). In the current study, we drew 
attention to a potential role FIH might play in epigenetic regulatory processes in response to 
low oxygen levels in FIH null muscle cells. 
 
Role of FIH as histone modifying enzyme? 
The canonical role of FIH as an asparagine hydroxylase of the HIF CTAD does not imply an 
obvious role for FIH in the nucleus. However, due to its small molecular weight its main 
form of transport is passive diffusion, and it is known that FIH can be actively transported to 
the nucleus when nuclear ankyrin proteins, such as Notch, are overexpressed (Zheng, 2008). 
This indicates that FIH hypothetically can access chromatin, and play a role in altering gene 
expression. 
FIH possesses a JmjC domain that is identical to domains histone demethylases own, 
supporting the hypothesis that FIH might function as a histone demethylase and by that 
mechanism regulate HIF target genes in a promoter-specific manner (Mahon PC, 2001; 
Trewick SC, 2005). The analysis included histone methylation marks known to be 
transcriptional repressors such as H3K9me2/me3, and transcriptional activators such as 
H3K4me2/me3, and we also monitored the H3K9ac epigenetic activation mark. And indeed, 
we identified significantly elevated methylation levels at the repression mark histone 3 lysine 
9 dimethyl at promoter regions of various metabolic HIF target genes (PHD3, PGK1, 
Aldolase A, Enolase 1, PFKFB3, Dec1) in FIH null mouse cells at normoxia and acute 
hypoxia, indicating FIH might specifically target H3K9me2 that is associated with 
transcriptional repression of potentially active genes. Note, muscle cells show the highest FIH 
expression levels in tissues (Zhang N, 2010). 
In line with these findings, we observed elevated global H3K9me2 levels in quadriceps 
muscles of female FIH null mice. Subsequent analysis led us to analyze FIH’s potential to act 
as a histone demethylase. With the help of an in vitro carbon dioxide capture assay, we 
analyzed the catalytic activity of FIH towards histone 3 and histone 3 lysine 9 dimethyl 
peptides. FIH cannot function as histone demethylase on its own. The not observed capacity 
of FIH to demethylate histones might be explained by incorrectly folded histones, deprivation 
of iron when mixed with histones, lack of an essential cofactor, or the fact that FIH plainly 
might not directly demethylate histones. 
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Role of FIH as modifier of histone modifying enzymes? 
To further investigate the role FIH might play in epigenetic regulation, we examined whether 
histone demethylases or methyl transferases might be targets of FIH. Recent work has 
demonstrated that other 2OG oxygenases catalyze histone demethylation reactions (Loenarz 
C and Schofield CJ, 2011). Another JmjC domain-containing enzyme, Jmjd6, has been 
shown to act as a histone arginine demethylase as well as a lysine hydroxylase (Chang B, 
2007; Webby CJ, 2009). Therefore, it appeared plausible that, in addition to the established 
oxygen-dependent regulation of HIF function via HIF hydroxylases, there are other targets 
and steps in the hypoxia signaling pathways that are controlled by FIH. Another report 
identified histone 3 lysine 9-specific demethylase Jmjd1a and methyl transferase G9a as HIF 
target genes (Beyer S, 2008). 
Given the histone methylation changes we observed at promoter regions of numerous genes, 
we hypothesized that FIH might regulate epigenetic changes by recruiting other proteins, 
such as the demethylase Jmjd1a, to HIF target gene promoters. Our findings demonstrate a 
correlation of loss of FIH and changes in Jmjd1a expression, indicating the protein 
hydroxylase and the histone demethylase might interact to regulate the epigenetic response 
observed at the histone 3 lysine 9 repression mark. Whether or not these changes result in 
direct FIH-Jmjd1a protein-protein interaction, has been subject to subsequent work. 
Preliminary studies showed no interaction of endogenous FIH and Jmjd1a. Further 
investigation is required to better understand the mechanisms that sequester FIH and restrict 
its cellular hydroxylase activity. 
 
Conclusion 
The work presented here shows fundamental restrictions. In this study, we have neither 
considered a wide range of other histone modifying enzymes nor a crosstalk that involves 
multiple histone-modifying complexes nor have we tried to identify FIH as part of such a 
complex. A key concern is FIH action has not been addressed as a question of context and 
time, hence, at the present, it seems premature to draw any conclusions about FIH’s 
involvement in the epigenetic response to changing oxygen levels. Lee and colleagues drew 
the conclusion that it is not sufficient to just look at a pattern of chromatin modifications at a 
locus to determine its gene expression status, indicating a crosstalk of modifications depend 
on each other. For example, it has been proposed that chromatin modifications establish a 
complex code recognized by transcription factors to determine the transcriptional state of a 
gene (Lee JS, 2010). The complexity seems overwhelming, as Zippo and colleagues report 
that in addition to histone modification crosstalk, the histone tails H3 and H4 seem to also 
interact. Furthermore, histone modifications appear to recruit opposing enzymes, for 
example, H3K4 and H3K36 methylation recruit both deacetylases and acetyl transferases 
(Zippo A, 2009). Through the present study, we have gained a new perspective of FIH 
metabolism. Unfortunately, more questions remain unanswered than new insights have been 
provided. Further work is essential to deepen our understanding of FIH as epigenetic 
modulator, involving possibly wider consequences as, for example, PHD3 has been reported 
to be specifically methylated in breast cancer cell lines. As abnormal profiles of histone 
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modifications result in a variety of pathological disease, future work might have implications 
beyond our understanding of FIH’s molecular action.     xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx
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4   SUMMARY  AND  FUTURE  PERSPECTIVES  
 
The present study was carried out in order to shed light on mechanisms of bHLH-Pas 
transcription factor regulation, specifically the AhR and the HIF signaling pathways. The 
main findings can be summarized as follows: 
(I)   To date, the AhR receptor is the only transcription factor in the bHLH family that 
possesses a second function. The receptor functions as a ligand-activated 
transcription factor or E3 ubiquitin ligase. The current study identified ARNT as 
key player in the modulation of the switch. Previous work by Ohtake and 
colleagues identified AhR and ARNT as part of the ubiquitin ligase complex. Our 
findings are contrary, as we fail to identify ARNT as part of the complex. AhRR 
plays another crucial role as it competitively dimerizes with ARNT and changes 
its availability, and thereby disrupts the transcriptional function of AhR. AhRR 
further reduces ERα protein levels and diminishes estrogen-dependent xenograft 
tumor growth. 
(II)   50-fold higher FIH levels in skeletal muscle compared to other tissues make the 
asparagine hydroxylase a perfect target for studying hypoxic effects on the cell’s 
changing energy demands. Interestingly, we found that FIH can even function as a 
regulating factor under hypoxia. This is mainly due to its high affinity to oxygen. 
Furthermore, FIH seems to “prepare” cells for a state of increased glycolytic 
energy generation caused by hypoxia. And indeed, FIH null cells show elevated 
glycolytic stores at normoxia and drive cells into a glycolytic metabolism in 
hypoxia. FIH has further effects during prolonged exercise. In normoxia, FIH 
shows an elevated oxidative metabolism, while at low oxygen levels we observe a 
shift from aerobic to an anaerobic metabolic state at increased exercise intensities. 
(III)   FIH serves as key regulator of the hypoxic response to low oxygen environments. 
However, FIH has been shown to possess HIF-independent functions, for 
example, FIH hydroxylates ARD-containing proteins. Furthermore, FIH protein 
contains a JmjC domain homologous to domains possessed by histone 
demethylases. FIH indeed seems to have a mediating function as we observed 
significantly increased methylation status at the transcriptional repression mark 
histone 3 lysine 9 dimethyl in promoter regions of metabolic HIF target genes in 
loss of FIH cells at normoxic and acute hypoxic oxygen levels. Finally, we 
observed correlations of loss of FIH and Jmjd1a expression. 
Further investigation will be key to deepen our understanding in the underlying mechanisms, 
including identification of specific HIF1α and HIF2α regulating pharmaceuticals, further 
characterization of co-activators, co-repressors, or collaborating transcription factors, and the 
role of ARNT. More work will be critical to elucidate the mechanism (a) how AhR’s 
ubiquitin ligase works, (b) how FIH can act as metabolic mediator, and (c) whether or not 
FIH plays a pivotal role in the epigenetic response to environmental changes. Further studies 
will reveal whether AhR or FIH can serve as therapeutic targets and whether we can develop 
therapeutic treatment regimen for various diseases, among others estrogen-dependent tumors 
(in case of AhR). 
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5   MY  ACADEMIC  ORGANIZATION  
 
The following is my very own point of view based on the experiences I gained during the last 
15 years at three different universities in three different countries – Sweden, Germany, and 
the US. My thoughts are not a reflection of the work at my previous labs, but rather general 
observations I made within the mentioned period of time. In all fairness, I have had insights 
into aspects of leadership training organized by the universities, but not in completion. 
If we ignore for a minute the special role a public university has (financed by tax payer’s 
money, creation of knowledge as central goal, aiming for scientific advancement, work for 
the good of mankind instead of financial interests), a university is nothing else than any other 
organization, in which a management team develops a strategy and establishes a certain 
working culture. 
 
As supporter of people first, my university as organization should have four major functions: 
(1) Establish a transparent hiring process, 
(2) Develop a well-functioning onboarding program, 
(3) Support its team leaders, and 
(4) Create an organization culture to thrive. 
 
1) Establish a transparent hiring process 
To date, I have not experienced any sort of organizational recruitment routine. I envision a 
university, in which employees are recruited not only dependent on their past merits, but also 
based on certain personality traits such as kindness, curiosity, innovative mindset and a high 
level of integrity. 
 
2) Develop a well-functioning onboarding program 
It must not only be in the university’s interest to recruit the right people, but upon acceptance, 
to help them become innovative leaders of their projects. I can only see this becoming a 
practical approach, if the university offers a program on innovation, entrepreneurship and 
design thinking before the start of the doctoral studies. To give the students the opportunity to 
master the literature of the given topic, this onboarding time may also include a thorough 
lecture-series on scientific principles, methods and topic-related studies. 
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3) Support their team leaders 
A scientific career is special and the path unique. Scientists become group leaders based on 
their individual achievements. Before long researchers run a team of 5 to 10+ people. Team 
leaders face so many challenges, hence, building a well-functioning team might at times get 
lower attention. Here I wished the university would support team leaders and help focus on 
developing their teams. Such support may include (but it is not restricted to) raising 
awareness about communicating a vision, establishing short-term but also long-term goals, 
performance appraisals, and team roles. Actual project management tools might be a great 
help to structure the student’s goals and help set key performance indicators (KPIs). The 
combination of a bottom-up and top-down approach might contribute to a higher level of 
responsibility, as students design projects and set goals by themselves. One last note on team 
development, scientific teams are built under the cover of “independent working”, which 
means nothing else than it is the sole responsibility of the student/scientist to address a 
scientific question in practice. I find it hard to understand why teams do not approach a 
certain question collaboratively. The base might be set by an individual before the whole 
team’s expertise combines in early stages (not only during a revision process) to then finish 
the project. In addition, a team approach guarantees a shared knowledge base, supports 
employee bonding, creates a shared standardized technological infrastructure, and establishes 
a common purpose. All this results in the formation of an empowered and self-managing 
team. 
 
4) Create an organization culture to thrive 
Culture is the single most important factor to run an organization successfully. Survival of the 
fittest is one way to run a scientific organization, another way is to put people first, 
communicate and honor scientific breakthrough, support young group leaders and group 
leaders in general, be fair, and create an environment of innovation and entrepreneurship. To 
all academic leaders out there, be passionate, innovative, social, creative, entrepreneurial, 
inspirational, and visionary! Your employees will pay back with their blood, sweat and tears. 
 
Finally, a complete change of the established academic system is such a radical idea that it 
won’t happen. However, it is fun to speculate how another approach might look like. The 
next level university might ensure full control over processes and roles by the university 
itself. The idea is based on the fact that the various roles in the lab could not be more 
different. Just imagine Master programs would address this and educate for purely lab-
related roles (methods, literature, presentation skills), writing roles (grant application, 
manuscript writing) and scientific team management roles (innovation, design thinking, 
speaking skills, people management, scientific literature). 
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